羟苯磺酸钙联合GLP-1类似物治疗糖尿病视网膜病变的临床意义  

Clinical significance of calcium hydroxide combined with GLP-1 in the treatment of diabetic retinopathy

作　　者：陈利荣[1] 姚军平[1] 张贻转[1] 周宇[1] 高波[1] 

机构地区：[1]武汉科技大学附属天佑医院眼科,湖北武汉430064

出　　处：《中国医院药学杂志》2017年第15期1505-1508,共4页Chinese Journal of Hospital Pharmacy

摘　　要：目的:探讨在2型糖尿病视网膜病变非增殖期的治疗阶段使用羟苯磺酸钙联合GLP-1类似物的临床效果与作用机制。方法:收集某院眼科收治的双眼非增殖性Ⅱ期、Ⅰ期轻度2型糖尿病视网膜病变患者60名使用平均随机的方法分成治疗组与对照组,治疗组患者采用口服羟苯磺酸钙50 mg联合皮下注射利拉鲁肽0.6 mg的方法进行治疗,对照组患者采用口服羟苯磺酸钙联合皮下注射生理盐水的方法进行治疗,在治疗之前对2组患者的眼底照相情况、外周血C肽水平、空腹血糖水平进行测量,在治疗6个月之后对患者进行随访,随后对患者眼底照相情况、外周血C肽水平、空腹血糖水平进行测量。结果:在6个月治疗之后治疗组患者视网膜病变程度要轻于对照组,治疗组外周血C肽水平高于对照组、空腹血糖水平要低于对照组。结论:羟苯磺酸钙联合GLP-1类似物的方法能够有效遏制2型糖尿病视网膜病变患者的进展。OBJECTIVE To investigate the clinical effects of the patients with non-insulin-dependent diabetes mellitus and diabetic retinopathy.METHODS Sixty patients with non-insulin-dependent diabetes mellitus and diabetic retinopathy were enrolled.All patients had the non-proliferative diabetic retinopathy of phaseⅠ orⅡ.Patients were divided into test group and control group by the stochastic and average way.The patients from test group were treated by calcium dobesilate capsules 50 mg and the liraglutide 0.6 mg,patients from the control group were treated by calcium dobesilate capsules and stroke-physiological saline solution.Before treatment and 6 months after treatment,C-peptide in peripheral blood and fasting blood glucose were detected,and fundus examination was performed.RESULTS After 6 mouths,compared to patients in control group,patients from the test group had lower fasting blood glucose,higher C-peptide in peripheral blood,and milder retinopathy.CONCLUSION Calcium dobesilate capsules combined with liraglutide can effectively inhibit progression of non-insulin-dependent diabetes mellitus and the diabetic retinopathy.

关 键 词：GLP-1类似物 利拉鲁肽 羟苯磺酸钙 糖尿病视网膜病变 

分 类 号：R961[医药卫生—药理学]